Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Non-Current Assets (2016 - 2025)

United Therapeutics' Non-Current Assets history spans 17 years, with the latest figure at $4.2 billion for Q4 2025.

  • For Q4 2025, Non-Current Assets rose 19.7% year-over-year to $4.2 billion; the TTM value through Dec 2025 reached $15.9 billion, up 22.81%, while the annual FY2025 figure was $4.2 billion, 19.7% up from the prior year.
  • Non-Current Assets for Q4 2025 was $4.2 billion at United Therapeutics, up from $3.9 billion in the prior quarter.
  • Across five years, Non-Current Assets topped out at $4.2 billion in Q4 2025 and bottomed at $780.9 million in Q4 2021.
  • The 5-year median for Non-Current Assets is $3.1 billion (2024), against an average of $2.9 billion.
  • The largest annual shift saw Non-Current Assets tumbled 68.1% in 2021 before it skyrocketed 226.24% in 2024.
  • A 5-year view of Non-Current Assets shows it stood at $780.9 million in 2021, then increased by 13.16% to $883.7 million in 2022, then increased by 21.06% to $1.1 billion in 2023, then surged by 226.24% to $3.5 billion in 2024, then rose by 19.7% to $4.2 billion in 2025.
  • Per Business Quant, the three most recent readings for UTHR's Non-Current Assets are $4.2 billion (Q4 2025), $3.9 billion (Q3 2025), and $4.1 billion (Q2 2025).